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Abstract. Berberine (BBr) is the main component of coptidis 
rhizoma, the dried rhizome of Coptis chinensis and is a poten-
tial plant alkaloid used for the treatment of cancer due to its high 
antitumor activity. The present study examined the therapeutic 
potential and molecular mechanism of action of BBr against 
Hcc, using systematic pharmacology combined with a molec-
ular docking approach and experimental validation in vitro. 
Through systematic pharmacological analysis, it was found that 
BBR serves a significant role in inhibiting HCC by affecting 
multiple pathways, especially the Pi3K/aKT signaling pathway. 
Furthermore, the docking approach indicated that the binding 
of BBr to aKT could lead to the suppression of aKT activity. 
The present study examined the inhibitory effect of BBr on 
the PI3K/AKT pathway in HCC and identified that BBR down-
regulated the expressions of phosphorylated aKT and Pi3K 
in MHcc97-H and HepG2 cells, inhibiting their growth, cell 
migration and invasion in a dose-dependent manner. in addi-
tion, inhibition of the aKT pathway by BBr also contributed to 
cell apoptosis in MHcc97-H and HepG2 cells. Taken together, 
the results of the present study suggested that BBr may be a 
promising antitumor drug for Hcc that acts by inhibiting the 
Pi3K/aKT pathway.
Introduction
Hepatocellular carcinoma (Hcc) is one of the most common 
types of cancer in humans, and in china alone accounts for 
53% of all liver cancer-related deaths worldwide (1,2), repre-
senting the second most common cause of cancer-related 
mortalities (3). Potential therapies for Hcc include local abla-
tive therapies, liver transplantation and resection. However, 
these therapies are effective only for treating Hcc at early 
stages (4). For advanced stages, systemic therapy with the 
tyrosine kinase inhibitor sorafenib is the best available option, 
as indicated by current data (5). Treatment with sorafenib 
presents various side effects, such as diarrhea, hypertension 
and skin toxicity (6). Therefore, understanding the molecular 
mechanisms involved in development of Hcc is essential to 
uncover novel drugs for targeted therapies. Berberine (BBr), 
a natural isoquinoline alkaloid (Fig. 1), is found in the roots, 
rhizome and stem bark of a number of important medicinal 
plants (7). in the clinical setting, BBr has been used for 
decades to treat patients who have diarrhea (8), acute radia-
tion intestinal syndrome (9) and type 2 diabetes mellitus (10), 
with doses of 0.1-0.3 g three times a day, 20 mg/kg once a 
day and 0.9 g once a day with negligible adverse reactions. 
Previous studies also have shown that BBr exhibits antitumor 
properties (11) against ovarian cancer (12), breast cancer (13), 
nasopharyngeal carcinoma (14), thyroid carcinoma (15) 
and prostate cancer (16), with the ic50 of BBr of 2.79 mg/l, 
26.5 µM, 11.7 µg/ml, 125.6 and 220.36 µM, respectively. BBr 
has been proposed to exhibit several antitumor activities that 
target multiple signaling pathways, for example the Pi3K/aKT 
pathway, that are crucial for tumor progression (17). despite 
several investigations, the precise cellular and molecular 
targets of BBr remain unknown (18). in addition, the molec-
ular mechanisms of action of BBr in Hcc have yet to be 
fully elucidated. Therefore, the present study investigated the 
potential anti-Hcc effect of BBr and examined its molecular 
mechanism of action using computer-aided approaches.
computer-aided approaches have been widely used in 
drug research to improve the efficiency of drug discovery. 
Systematic pharmacology is an emerging field that combines 
multiple drug target prediction, oral bioavailability prediction 
and network analysis to understand the active compounds 
and therapeutic targets of Traditional chinese medicine 
(TcM) (19). as a receptor-based computer-assisted drug 
design approach, molecular docking mainly predicts the 
interactions between two or several molecules based on both 
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geometry and energy match (20). as for other tumors, many 
emerging treatments of Hcc need further evaluation (5). 
efforts are underway to explore the molecular mechanisms 
for the treatment of Hcc and for the development of novel 
therapeutic approaches with lower toxicity. The present study 
provided in vitro experimental evidence to validate the mecha-
nisms of action of BBr in treating Hcc at the molecular level, 
as were predicted by systems pharmacology and molecular 
docking results.
Materials and methods
Evaluation of pharmacokinetic properties by TCM systems 
pharmacology (TCMSP). TcMSP (http://lsp.nwu.edu.cn/
tcmsp.php; version 2.3) is an open-source systems pharma-
cology platform for TcM that provides information on the 
interactions among drugs, targets and diseases. This database 
includes herbal products, chemicals, targets, drug-target 
networks and drug-target-disease networks; as well as 
pharmacokinetic properties of natural ingredients including 
drug-likeness (dl), oral bioavailability (oB), fractional nega-
tive accessible surface area (FaSa-), blood-brain barrier 
(BBB), caco-2 permeability (caco-2) and lipinski's rule of 
five [molecular weight (MW), total polar surface area (TPSA), 
octanol‑water partition coefficient (ALogP), H‑bond donor 
(Hdon) and H-bond acceptor (Hacc)] (21). in the present study, 
the molecular name ʻberberine̓ was searched in TCMSP 
and the drug-like properties of BBr were analyzed at the 
molecular level.
Target fishing by TCMSP and PharmMapper. The puta-
tive targets of BBr were collected from two databases, 
TcMSP and PharmMapper (http://www.lilab-ecust.cn/
pharmmapper/; updated: april 10, 2019) (22). TcMSP 
is a useful analysis platform and knowledge repository. 
drug-target mappings were collected from two sources in 
TcMSP: experimentally validated targets were obtained 
from the database for Herb ingredients' Target (http://
lifecenter.sgst.cn/hit/; downloaded on July 28, 2018) and 
the Systems drug Targeting (https://targetingsystems.net/; 
downloaded on July 30, 2018) model construction was used 
to predict potential targets that were not validated. Support 
Vector Machine score (SVM) ≥0.7 and Random Forest score 
(RF) ≥0.8 were set as the threshold to identify candidate 
targets (23). PharmMapper, a free web server, can identify 
potential drug targets using the pharmacophore mapping 
approach. A mol2 file for BBR was obtained from TCMSP 
database and uploaded in PharmMapper.
HCC‑significant target selection. Hcc-significant targets 
were obtained from two databases including oncodB.Hcc 
(http://oncodb.hcc.ibms.sinica.edu.tw/index.htm; downloaded 
on august 13, 2018) and liverome (http://liverome.kobic.
re.kr/; downloaded on august 14, 2018). oncodB.Hcc is a 
comprehensive tumor genomic database that displays abnormal 
cancer related target genes and loci seen in Hcc (24); while 
liverome is a database of genes associated with Hcc. in 
these databases, gene signatures are mostly from proteomics 
studies and published microarray data manually assembled 
and annotated (24).
Protein‑protein interaction (PPI) data. The protein-protein 
interaction (PPi) data were obtained from Search Tool for the 
retrieval of interacting Genes/Proteins (STrinG) database 
(http://string-db.org/; version 10) (25), with the species limited 
to ʻHomo sapiens .̓
Gene Ontology (GO) and pathway enrichment analysis. Go 
and Kyoto encyclopedia of Genes and Genomes (KeGG) 
pathway enrichment analysis were performed using database 
for annotation, Visualization and integrated discovery 
(daVid; http://david.abcc.ncifcrf.gov/; version 6.8) (26,27).
Network construction and analysis. construction of BBr-BBr 
targets network and PPi networks were visualized using 
cytoscape (http://cytoscape.org/; version 3.6.0) (28).
Molecular docking algorithm. Before the docking process, 
the three-dimensional (3d) crystal structures of aKT 
were obtained in the PdB format from rcSB Protein data 
Bank (http://www.pdb.org/; PdB-id:3MVH; released: 
June 2, 2010) and prepared with autodock 4.2 (http://
autodock.scripps.edu/;version 1.2) for flexible docking studies. 
The 3d structure of BBr (Pubchem cid: 2335) was obtained 
from ncBi-Pubchem (https://pubchem.ncbi.nlm.nih.gov/), 
energy optimization was performed with ChemOffice (http://
www.cambridgesoft.com; version 17.0) and saved in the PdB 
format. Gasteiger charges were added, rotatable bonds were 
set by the autodock tools and all torsions were allowed to 
rotate. Polar hydrogen atoms were added to the protein using 
autodock tools. The grid map was centered at the active site 
pocket of the protein by autogrid (version 1.4.5) (29). The 
root‑mean‑square deviation value was less than 2.0 Å. Briefly, 
to perform docking in autodock 4.2, the grid dimensions were 
established using the grid center, number of points (X: 60, 
Y: 60, Z: 60) and spacing (0.375 Å). Molecular docking was 
performed and analyzed using autodock 4.2. a lamarckian 
genetic algorithm method (runs 100) was implemented in 
the program suite to identify appropriate binding modes and 
conformation of the ligand molecules (30). a maximum of 25 
million energy evaluations were applied for the experiment. 
The results were clustered using a tolerance of 2.0 Å. analysis 
of BBr and target protein docking results using Pymol (https://
pymol.org/2/; version 2.3) and ligplot (https://www.ebi.ac.uk/
thornton-srv/software/ligPlus/; version 1.4).
Cell lines, culture conditions and reagents. MHcc97-H 
and HepG2 cell lines were obtained from the cell Bank of 
the chinese academy of SciencHes (Shanghai, china). The 
cells were cultured in dMeM (Thermo Fisher Scientific, 
inc.) containing 10% heat inactivated FBS (Thermo Fisher 
Scientific, inc.), 100 u/ml penicillin and 100 µg/ml strep-
tomycin and maintained as monolayer in a humidified 
atmosphere of 95% air and 5% co2 at 37˚C. Culture medium 
was replaced every 2 days. BBr was purchased from chengdu 
desite chemical co. ltd. and a stock solution of 10 mM was 
prepared in dMSo (Sigma-aldrich; Merck KGaa). The solu-
tion was serially diluted in dMeM immediately before the 
experiments. Pancreatin, penicillin and streptomycin were 
purchased from Gibco (Thermo Fisher Scientific, Inc.). All the 
reagents were of analytical grade.
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Western blotting. Following treatment with different concen-
trations of BBr for 24 h, MHcc97-H and HepG2 cells were 
harvested and washed with ice-cold PBS. Total cellular protein 
was extracted by lysing cells in buffer containing 50% glyc-
erol, 10% SdS, 0.5 M Tris/Hcl (pH 6.8), 1:100 proteases and 
phosphatases inhibitor cocktail. Protein concentrations were 
determined using the Bca method (Beyotime institute of 
Biotechnology). Then, 50 µg protein was separated by 10% 
SdS PaGe and transferred onto PVdF membranes (Bio-rad 
laboratories, inc.). Membranes were blocked with 5% BSa 
(Gibco; Thermo Fisher Scientific, inc.) in TBST (0.1% 
TWeen) for 2 h at room temperature. The membranes were 
incubated overnight at 4˚C with appropriate primary anti-
bodies including anti-Pi3K p85-α (1:1,000; cat. no. ab182651; 
abcam), anti-aKT (1:1,000; cat. no. 9272; cell Signaling 
Technology, inc.), anti-phosphorylated (p-) aKT (1:1,000; 
cell Signaling Technology, inc.) and β-actin (1:6,000; ab8227; 
abcam). after being incubated with HrP-conjugated goat 
anti-rabbit (1:1,000; ab181662; abcam) or anti-mouse igG 
(1:1,000; ab205719; abcam) for 1 h at room temperature, 
immune complexes were detected using enhanced chemilumi-
nescence (ecl kit; eMd Millipore). Protein expression levels 
were normalized to β‑actin and quantified using Image Lab 
software version 6.0.1 (Bio rad laboratories, inc).
Cell viability assay. cells were collected by trypsinization 
(Ge Healthcare life Sciences) after replacing the medium 
twice. The cells were cultured in 96-well plates at a density of 
5x104 cells per well. after 24 h of incubation, cells were treated 
with various concentrations of BBr (50, 100 and 200 µM) 
and cultured for 24 h. The cells in the logarithmic growth 
phase were used for detecting cell viability using the MTT 
assay. at the end of the incubation, 10 µl of MTT solution 
(Sigma-aldrich; Merck KGaa) was added to each well and 
incubated for another 2.5 h. dMSo (100 µl) was used to 
dissolve formazan crystals and absorbance was detected at 
wavelength of 570 nm with a microplate reader.
Colony formation assay. MHcc97-H and HepG2 cells in the 
logarithmic phase were dispersed into single cells by trypsin 
digestion. cell suspensions containing 1,000 cells were seeded 
in six-well plates with complete medium and the plates were 
incubated for two weeks. The medium was removed and the 
plates were washed twice with PBS, after which the cells were 
fixed with paraformaldehyde for 15 min and stained with 
crystal violet solution for 15 min at room temperature. after 
washing, the cells were air-dried and the number of colonies 
was calculated for each group.
Flow cytometry for cell apoptosis analysis. BBr-induced 
apoptosis in MHcc97-H and HepG2 cells was quantitatively 
determined by flow cytometry using the annexin V-FiTc 
apoptosis detection kit (Vazyme) and a flow cytometer 
(FACSCalibur; BD Biosciences). Briefly, after treatment with 
BBr for 24 h, cells were collected by using 0.25% trypsin 
and washed twice with cold PBS for 5 min, washed with PBS 
and incubated with alexa 488 and propidium iodide (Pi) for 
cellular staining at room temperature for 10 min in the dark. 
The stained cells were analyzed by cell Quest acquisition 
software (version 3.3; Bd Biosciences).
Wound healing assay. Wound healing assay was performed 
to evaluate the migration ability of cells. cells were seeded 
5x105 cells per well in 6-well plates and allowed to adhere for 
24 h. Confluent monolayer cells were scratched using a 20 µl 
pipette tip and then washed three times with 1X PBS to clear 
cell debris and suspension cells. Medium containing 1% FBS 
and BBr (50-200 µM) was added and the cells were allowed 
to close the wound for 48 h. images were acquired under an 
fluorescence microscope (Model DMi8, Leica Microsystems 
GmbH) at 0, 24 and 48 h at the same position of the wound 
(magnification, x10). The migration distance was calculated by 
the change in wound size during the 24 and 48 h period using 
adobe Photoshop cS6 software (adobe Systems, inc.). The 
experiment was performed in triplicate.
Transwell assay. a 24-well Transwell plate (8-mm pore size; 
corning, inc.) was used to measure the migratory and invasive 
ability of each cell line. The inserts in the Transwell were 
coated with a thin layer of 0.25 mg/ml Matrigel Basement 
Figure 1. Structure of berberine. chemical structure of berberine (left); and energy-minimized 3d structure of berberine (right).
SonG et al:  eXPlorinG BBr aGainST Hcc BY SYSTeMaTic PHarMacoloGY and eXPeriMenTal ValidaTion 4657
Membrane Matrix (BD Biosciences) at 37˚C for 30 min. 
MHcc97-H and HepG2 cells were treated with BBr for 24 h, 
trypsinized and seeded into the upper Transwell chamber 
(2.5x104 cells) in 100 µl of serum-free medium. complete 
medium (600 µl) containing 10% FBS was added to the lower 
chamber. Triplicate wells were used for each group. The cells 
were allowed to migrate through the filters for 48 h at 37˚C 
in a humidified incubator with 5% CO2. cells attached to the 
lower surface of the membrane were fixed in 4% paraformal-
dehyde for 30 min and stained with 0.1% crystal violet at room 
temperature. The cells on the upper surface of the filters were 
removed by wiping with a cotton swab. The number of stained 
cells on the lower surface of the filters was counted at x20 
magnification under a fluorescence microscope (Model DMi8; 
Leica Microsystems GmbH). A total of five fields of view were 
counted for each Transwell filter.
Statistical analysis. data are presented as the mean ± SeM. 
all statistical analyses were performed with SPSS 19.0 
statistical software (iBM corp.). The data are expressed 
as the mean ± SeM. Statistical analysis was performed by 
one-way anoVa followed by Tukey's multiple comparison 
test. Western blot analysis was repeated at least three times. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Pharmacokinetic properties and putative targets of BBR. 
Pharmacokinetic properties play a vital role in drug discovery. 
Pharmacokinetic properties for BBr including caco-2 
permeability, dl, FaSa-, oB, BBB and lipinski's rule of 
five (MW, TPSA, AlogP, Hdon, Hacc) were obtained from 
TcMSP (Table i).
a total of 230 putative targets were predicted for BBr by 
TcMSP and PharmMapper, and duplicated potential targets 
were removed. detailed information on candidate targets are 
provided in Table Si.
BBR‑BBR targets network analysis. as shown in Fig. 2, a graph 
of BBr-BBr targets interaction was constructed based on 231 
nodes (one compound and 230 candidate targets) and 230 
edges. BBr-BBr targets network analysis displayed that BBr 
targeted proteins including aKT1, PTGS2, PdK2, MMP2, 
MMP8, cdK2, cdK6, caSP3, caSP1, alB and GSK3B. 
Multiple targets predicted as hits for BBr in this network may 
be critical to the treatment of Hcc. Previous research has 
shown MMP2 may act as an oncogene in Hcc (31), and high 
expression of cdK2 may be more aggressive in Hcc (32).
Identification of targets related to HCC. The present study 
identified 611 and 6,927 Hcc-significant targets from 
oncodB. Hcc and liverome, respectively. as displayed in 
Table Sii, 167 candidate targets were obtained, and duplicated 
candidate targets were deleted.
in order to validate the molecular mechanisms of BBr 
acting on Hcc, a PPi network analysis and a Go and pathway 
enrichment analysis on the common targets of BBr and 
HCC‑significant targets were conducted.
PPI network of HCC‑significant targets. The protein-protein 
interaction network of the common targets was constructed 
using the STrinG database. only one target did not show any 
protein-protein interactions, while two targets could not be 
found in the above database. a total of 164 nodes and 1,292 
edges (Fig. 3) are shown in this network. in total, 12 genes, 
including ALB, AKT1, SRC, IGF1, EGFR, HSP90AA1, ESR1, 
CASP3, F2, MAPK14, MMP9 and PTGS2, with degree ≥40, 
were selected as key genes. a large number of edges were 
obtained for each node (101 for ALB, 74 for AKT1, 62 for SRC, 
57 for IGF1, 57 for EGFR, 56 for HSP90AA1, 53 for ESR1, 47 
for CASP3, 44 for F2, 44 for MAPK14, 43 for MMP9 and 41 
for PTGS2). The results of the PPi network analysis revealed 
that these key genes may play important roles in the treatment 
of Hcc.
GO and pathway enrichment analysis for target genes. To 
identify the biological function of the candidate targets, 
functional enrichment analysis was performed using daVid 
database. The detailed results of Go terms and pathways are 
presented in Table Siii. Go analysis suggested that the cellular 
components were related to cytosol, extracellular exosome, 
mitochondrion, nucleoplasm, extracellular region, extracel-
lular space, cytoplasm, mitochondrial matrix, focal adhesion 
and receptor complex (Fig. 4a).The biological processes in 
which the targets were involved were related to protein auto-
phosphorylation, steroid hormone mediated signaling pathway, 
transcription initiation from rna polymerase ii promoter, 
response to drug, peptidyl-tyrosine phosphorylation, positive 
regulation of phosphatidylinositol 3-kinase signaling, positive 
regulation of erK1 and erK2 cascade, purine-containing 
compound salvage and intracellular receptor signaling pathway 
(Fig. 4B). The molecular function terms were associated with 
steroid hormone receptor activity, protein tyrosine kinase 
activity, drug binding, protein homodimerization activity, 
transmembrane receptor protein tyrosine kinase activity, aTP 
binding, enzyme binding, identical protein binding and steroid 
binding (Fig. 4c). These results suggested that these biological 
characteristics played a critical role in the treatment of Hcc 
Table i. Pharmacokinetic properties of berberine.
name oB (%) dl BBB caco-2 MW TPSa alogP Hdon Hacc FaSa-
Berberine 36.86 0.78 0.57 1.24 336.39 40.80 3.45 0 4 0.19
oB, oral bioavailability; dl, drug-likeness; BBB, blood-brain barrier; caco-2, caco-2 permeability; MW, molecular weight (g/mol); TPSa, 
total polar surface area; AlogP, octanol‑water partition coefficient; Hdon, H‑bond donor; Hacc, H‑bond acceptor; FASA‑, fractional negative 
accessible surface area.
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Figure 3. Protein-protein interaction network constructed using STrinG. STrinG, Search Tool for the retrieval of interacting Genes/Proteins.
Figure 2. BBr-BBr targets network. The network consists of berberine and 230 berberine targets (Yellow V represents BBr, blue circles represent potential 
targets, and edges represent the relationships between BBr and potential BBr targets). BBr, berberine.
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by BBr. Kyoto encyclopedia of Genes and Genomes (KeGG) 
pathways indicated that pathways in cancer, Pi3K-akt 
signaling pathway, proteoglycans in cancer, prostate cancer, 
metabolism of xenobiotics by cytochrome P450, chemical 
carcinogenesis, small cell lung cancer, progesterone-mediated 
oocyte maturation, ras signaling pathway and thyroid hormone 
signaling pathway, were involved in the therapy of Hcc with 
BBr (Fig. 4d). Taken together, the above results showed that 
Pi3K/aKT signaling pathway may potentially serve a key role 
in the BBr treatment process of Hcc.
Docking of BBR to AKT. after applying the molecular docking 
approach according to the visual ligand-protein docking 
results, an in silico analysis was used to determine the binding 
site of BBr on aKT. The binding energy of BBr and aKT 
(PdB-id:3MVH) was -8.83; BBr could be docked into the 
active site of aKT. Secondly, BBr was found to compete 
with aTP for the aTP-binding site of aKT, to which it bound 
tightly by forming hydrogen bonds with the backbone amino 
and carbonyl groups of the corresponding residues (lys-158, 
ala-230) and also by establishing hydrophobic contacts 
Figure 4. Enriched GO terms. The top 15 significantly enriched terms of the targets genes in (A) cellular component, (B) biological process and (C) molecular 
function. Go, gene ontology.
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(Gly-159, Gly-157, leu-156, Val-164, ala-177, Met-281, Tlu-211, 
Tlu-291, Tyr-229, Phe-438) with side chains of surrounding 
residues. The inhibitory activities were confirmed with 
molecular docking analysis when considering H-bond interac-
tion, electrostatic potential energy, hydrophobic interaction of 
ligand molecules in the active pocket of aKT (Fig. 5). These 
results demonstrated that the binding of BBr to the active site 
of aKT could potentially suppress its activation, which could 
contribute to the inhibitory effects of BBr on proliferation and 
migration of Hcc.
BBR inhibits cell growth and induces cell apoptosis of 
MHCC97‑H and HepG2 cells. Viability and proliferation 
of MHcc97-H and HepG2 cells were assessed by MTT and 
colony formation assays, respectively. BBR treatment signifi-
cantly inhibited the growth of MHcc97-H and HepG2 cells 
(Fig. 6a) when treated BBr for 24 h. With the increase of 
concentration, the inhibition rate of cells increased signifi-
cantly. consistently, BBr decreased colony numbers of 
MHcc97-H and HepG2 cells at all indicated doses (Fig. 6B). 
These data suggested that the inhibitory effects of BBr 
could contribute to the suppression of Hcc cell viability and 
proliferation. To further investigate the effect of BBr treat-
ment on cell apoptosis, flowcytometry was performed using 
an annexin V-FiTc/Pi kit. in the present study, both early 
(a-V-SP) and late (Pi-SP) apoptotic cells were counted, as 
shown in the lower right and the upper right quadrant of the 
scatter plots, respectively. as demonstrated in Fig. 6c, after 
a 24-h treatment of HepG2 cells with BBr, the percentages 
of total apoptotic cells were: 4.2% (0 µM, vehicle treated 
control), 4.7% (50 µM), 5.6% (100 µM) and 16.9% (200 µM). 
For MHcc97-H cells, the percentages of total apoptotic cells 
Figure 4. Continued. (D) Top 15 significantly pathways in pathway enrichment analysis for potential targets (P<0.05). GO, gene ontology.
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were: 10% (0 µM, vehicle treated control), 11.8% (50 µM), 
16% (100 µM) and 33% (200 µM).
BBR suppresses cell migration and invasion of MHCC97‑H 
and HepG2 cells. as Pi3K/aKT pathway plays a critical role 
in cancer cell migration, the effects of BBr on the invasion 
and migration ability of Hcc cells were investigated. To this 
end, wound healing and Transwell chamber migration assays 
were performed in vitro. The relative migrated distance in 
BBR treated group was significantly smaller than that in the 
non-treated group, at indicated time points (P<0.05; n=3; 
Fig. 7a). Matrigel matrix invasion assay further indicated BBr 
treatment suppressed Hcc cell migration (Fig. 7B).
BBR inhibits PI3K/AKT signaling pathway in HCC cells. To 
confirm the effect of BBR on PI3K/AKT signaling pathway, 
changes in Pi3K/aKT effector proteins in Hcc cells were 
analyzed by western blotting. as shown in Fig. 8, Hcc cells 
possessed a high basal level of Pi3K and p-aKT, indicating 
that Hcc cells potentially rely on Pi3K/aKT for proliferation 
and migration. However, BBR treatment significantly inhibited 
the levels of Pi3K and p-aKT without affecting the total aKT 
protein. Further, aKT phosphorylation was suppressed in a 
BBr concentration-dependent manner (Fig. 8). This implied 
a potential relationship between the inhibitory effects of BBr 
on cancer cell growth and migration and the suppression of the 
Pi3K/aKT pathway.
Discussion
Over the past few decades, there has been a significant decline 
in the rate of novel phytochemicals that have been translated 
into effective drugs. currently, the most important problem 
for novel drug development is a lack of therapeutic efficacy 
in clinical trials accounting for 33% of failures (33). Thus, 
to maximize drug efficacy in pharmaceutical development, 
network pharmacology has been recently introduced to 
analyze the biological network of drug candidates, in order 
to design poly-target phytochemicals. Previous studies have 
shown that BBr potentially represses tumor progression by 
inhibiting cell proliferation (34), inducing cell cycle arrest and 
cell death, in various cancer cells (35,36). in the present study, 
Figure 5. ligand interaction and binding diagrams of BBr in the active site of aKT. (a) 3d interaction diagram obtained using PyMol. BBr forms hydrogen 
bonds (lys-158, ala-230) with proteins. Hydrogen bond represented by yellow dashed line. (B) electrostatic surfaces of BBr and aKT obtained using 
PyMol. lower electrostatic potential denotes better binding ability. BBr colored. (c) 2d schematic of interactions by ligplot. BBr, berberine.
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PPi network analysis revealed that AKT1, ALB, SRC, IGF1, 
EGFR, HSP90AA1, ESR1, CASP3, F2, MAPK14, MMP9 and 
PTGS2 could be the key genes that are essential for the survival 
of Hcc. Pathway analysis elucidated that Pi3K/aKT signaling 
pathway in cancer may be closely related to the progress of 
Hcc. The present study hypothesized that BBr potentially 
suppresses Hcc progression by regulating aKT, based on the 
network pharmacology study results.
aKT is a serine-threonine kinase and a vital component of the 
Pi3K/aKT/mammalian target of rapamycin signaling pathway. 
it is over-expressed in most types of cancer (37). activated 
aKT phosphorylates downstream signaling molecules such as 
GSK3β, PraS40, Bad and p70S6K, that promote survival, 
proliferation, growth and metastasis of cancer cells (38). due 
to its central role in these pathways, inhibition of aKT is an 
attractive intervention strategy for the treatment of cancer (39). 
in the present study, the docking approach indicated that the 
binding potential between BBr and aKT (rac-α serine/
threonine-protein kinase) could lead to suppression of aKT 
activity. The inhibitory effect of BBr on Pi3K/aKT pathway 
in Hcc was validated and it was found that BBr could down-
regulate the expressions of p-aKT and Pi3K in MHcc97-H 
and HepG2 cells, which could then inhibit the growth, cell 
migration and invasion of MHcc97-H and HepG2 cells in a 
dose-dependent manner. in addition, aKT pathway inhibition 
Figure 6. BBr decreases cell viability and induces cell apoptosis of 
MHcc97-H and HepG2 cells in a dose dependent manner. (a) MHcc97-H 
and HepG2 cells were treated with BBr at various concentrations for 24 h 
and processed for MTT assay. all data are presented as the mean ± standard 
error of mean (n=3), *P<0.05 vs. control group (non-berberine-treated) of the 
same cell line. (B) colony formation assay was performed in MHcc97-H 
and HepG2 cells incubated with BBr. Histogram indicating the colony 
number of each group based on replicates of the colony formation assay 
(n=3). ***P<0.001 vs. the control group. #P<0.05. (c) Hcc cells were treated 
with varying concentrations of BBr in complete medium for 24 h. cell apop-
tosis was examined by flow cytometry using Annexin V/PI double staining 
following the manufacturer's protocol. The lower right quadrant of the FacS 
histograms indicates the percentage of early apoptotic cells and the upper 
right quadrant indicates the percentage of late apoptotic cells. The data are 
presented as mean ± standard error of mean (n=3). Significant difference 
vs. control group (non-berberine-treated), *P<0.05, ***P<0.001 vs. vehicle; 
#P<0.05 and ##P<0.01. BBr, berberine.
Figure 7. BBr inhibits invasion and migration of MHcc97-H and HepG2 
cells in a dose-dependent manner. (a) Wound-healing assay for migration 
in cells. The scar closure area was detected by measuring the distance of 
the wound surface healing after treatment with BBr. (B) Following treat-
ment, the cell invasion ability was significantly inhibited in a dose‑dependent 
manner. all bar graphs are presented as mean ± standard error of mean (n=3). 
*P<0.05, **P<0.01 and ***P<0.001 vs. the control group. BBr, berberine.
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by BBr also contributed to cell apoptosis in MHcc97-H and 
HepG2 cells. Based the current study, 100 µM is the ideal 
concentration of BBr in potential treatment. However, there are 
some limitations in the present study. For example, a lack of 
caspase inhibition experiment, which may also be relevant for 
the anti-Hcc mechanism. in the future, further systematic and 
in-depth studies investigating the mechanism of anti-Hcc will 
be conducted. in conclusion, the use of BBr as a sensitizer of 
cancer cells to aKT inhibitors should be further explored by 
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